Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for mild traumatic brain injury
ACTRN12618001371280Phase 2Not yet recruiting
- Sponsor
- Nelson Marlborough District Health Board
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of acetylcysteine in traumatic brain injury (TBI) (2 arms), sponsored by Nelson Marlborough District Health Board. Primary endpoint: Proportion of patients symptom free at one week. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
acetylcysteine
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on ACTRN12618001371280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001371280.